Circulating 25-hydroxyvitamin D and prostate cancer survival

Cancer Epidemiology Biomarkers and Prevention

Volumn 25, Issue 4, 2016, Pages 665-669

  Mondul, Alison M ^a,b   Weinstein, Stephanie J ^a   Moy, Kristin A ^a   Mannisto, Satu ^c   Albanes, Demetrius ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ALPHA TOCOPHEROL; BETA CAROTENE; 25-HYDROXYVITAMIN D; VITAMIN D;

AGED; ARTICLE; BLOOD SAMPLING; CANCER MORTALITY; CANCER SURVIVAL; CONTROLLED STUDY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; VITAMIN SUPPLEMENTATION; ANALOGS AND DERIVATIVES; BLOOD; DOUBLE BLIND PROCEDURE; MIDDLE AGED; MORTALITY; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIAL; SURVIVAL ANALYSIS;

AGED; DOUBLE-BLIND METHOD; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; VITAMIN D;

EID: 84962434118     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-15-0991     Document Type: Article

References (23)

1. Giovannucci E. The epidemiology of vitamin D and cancer incidence and mortality: areview (United States). Cancer Causes Control 2005;16:83-95.
2. Holick MF. Vitamin D status: measurement, interpretation, and clinical application. Ann Epidemiol 2009;19:73-8.
3. Holick MF. Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. Am J Clin Nutr 2004;79:362-71.
4. Schwartz GG, Hulka BS. Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res 1990;10:1307-11.
5. Xu Y, Shao X, Yao Y, Xu L, Chang L, Jiang Z, et al. Positive association between circulating 25-hydroxyvitamin D levels and prostate cancer risk: new findings from an updated meta-analysis. J Cancer Res Clin Oncol 2014;140:1465-77.
6. Schenk JM, Till CA, Tangen CM, Goodman PJ, Song X, Torkko KC, et al. Serum 25-hydroxyvitamin D concentrations and risk of prostate cancer: results from the Prostate Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev 2014;23:1484-93.
7. Kristal AR, Till C, Song X, Tangen CM, Goodman PJ, Neuhauser ML, et al. Plasma vitamin D and prostate cancer risk: results from the Selenium and Vitamin E Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev 2014;23:1494-504.
8. DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 2014;64:252-71.
9. Shui IM, Mucci LA, Kraft P, Tamimi RM, Lindstrom S, Penney KL, et al. Vitamin D-related genetic variation, plasma vitamin D, and risk of lethal prostate cancer: a prospective nested case-control study. J Natl Cancer Inst 2012:104:690-9.
10. Shui IM, Mondul AM, Lindstrom S, Tsilidis KK, Travis RC, Gerke T, et al. Circulating vitamin D, vitamin D-related genetic variation, and risk of fatal prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Cancer 2015;121:1949-56.
11. Albanes D, Mondul AM, Yu K, Parisi D, Horst RL, Virtamo J, et al. Serum 25-hydroxy vitamin D and prostate cancer risk in a large nested case-control study. Cancer Epidemiol Biomarkers Prev 2011;20:1850-60.
12. Gupta D, Trukova K, Popiel B, Lammersfeld C, Vashi PG. The association between pre-treatment serum 25-hydroxyvitamin D and survival in newly diagnosed stage IV prostate cancer. PLoS One 2015;10:e0119690.
13. Holt SK, Kwon EM, Peters U, Ostrander EA, Stanford JL. Vitamin D pathway gene variants and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2009;18:1929-33.
14. Tretli S, Hernes E, Berg JP, Hestvik UE, Robsahm TE. Association between serum 25(OH)D and death from prostate cancer. Br J Cancer 2009;100: 450-4.
15. The alpha-tocopherol, beta-carotene lung cancer prevention study: design, methods, participant characteristics, and compliance. The ATBC Cancer Prevention Study Group. Ann Epidemiol 1994;4:1-10.
16. Pietinen P, Hartman AM, Haapa E, Rasanen L, Haapakoski J, Palmgren J, et al. Reproducibility and validity of dietary assessment instruments. II. A qualitative food frequency questionnaire. Am J Epidemiol 1988;128: 667-76.
17. Ersfeld DL, Rao DS, Body JJ, Sackrison JL Jr., Miller AB, Parikh N, et al. Analytical and clinical validation of the 25 OH vitamin D assay for the LIAISON automated analyzer. Clin Biochem 2004;37:867-74.
18. Gallicchio L, Helzlsouer KJ, Chow WH, Freedman DM, Hankinson SE, Hartge P, et al. Circulating 25-hydroxyvitamin D and the risk of rarer cancers:Design and methods of the Cohort Consortium Vitamin DPooling Project of Rarer Cancers. Am J Epidemiol 2010;172:10-20.
19. Holt SK, Kolb S, Fu R, Horst R, Feng Z, Stanford JL. Circulating levels of 25-hydroxyvitamin D and prostate cancer prognosis. Cancer Epidemiol 2013; 37:666-70.
20. Mondul AM, Shui IM, Yu K, Travis RC, Stevens VL, Campa D, et al. Genetic variation in the vitamin d pathway in relation to risk of prostate cancer-results from the breast and prostate cancer cohort consortium. Cancer Epidemiol Biomarkers Prev 2013;22:688-96.
21. Lokeshwar BL, Schwartz GG, Selzer MG, Burnstein KL, Zhuang SH, Block NL, et al. Inhibition of prostate cancer metastasis in vivo: a comparison of 1, 23-dihydroxyvitamin D (calcitriol) and EB1089. Cancer Epidemiol Biomarkers Prev 1999;8:241-8.
22. Krishnan AV, Shinghal R, Raghavachari N, Brooks JD, Peehl DM, Feldman D. Analysis of vitamin D-regulated gene expression in LNCaP human prostate cancer cells using cDNA microarrays. Prostate 2004;59:243-51.
23. Tokar EJ, Webber MM. Cholecalciferol (vitamin D3) inhibits growth and invasion by up-regulating nuclear receptors and 25-hydroxylase (CYP27A1) in human prostate cancer cells. Clin Exp Metastasis 2005; 22:275-84.